Centessa Pharmaceuticals plc (NASDAQ:CNTA) CEO Saurabh Saha Sells 2,592 Shares

Centessa Pharmaceuticals plc (NASDAQ:CNTA) CEO Saurabh Saha sold 2,592 shares of the company’s stock in a transaction on Wednesday, October 23rd. The shares were sold at an average price of $15.32, for a total value of $39,709.44. Following the sale, the chief executive officer now owns 630,661 shares of the company’s stock, valued at approximately $9,661,726.52. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.

Saurabh Saha also recently made the following trade(s):

• On Monday, October 21st, Saurabh Saha sold 22,205 shares of Centessa Pharmaceuticals stock. The shares were sold at an average price of $15.80, for a total value of $350,839.00.
• On Friday, September 20th, Saurabh Saha sold 55,000 shares of Centessa Pharmaceuticals stock. The shares were sold at an average price of $16.53, for a total value of $909,150.00.
• On Tuesday, September 10th, Saurabh Saha sold 175,000 shares of Centessa Pharmaceuticals stock. The shares were sold at an average price of $16.52, for a total value of $2,891,000.00.
• On Thursday, August 22nd, Saurabh Saha sold 506 shares of Centessa Pharmaceuticals stock. The shares were sold at an average price of $12.23, for a total value of $6,188.38.
• On Tuesday, August 20th, Saurabh Saha sold 4,169 shares of Centessa Pharmaceuticals stock. The shares were sold at an average price of $12.32, for a total value of $51,362.08.

Centessa Pharmaceuticals Price Performance

Centessa Pharmaceuticals stock traded down $0.31 during midday trading on Wednesday, reaching $15.15. 216,037 shares of the stock traded hands, compared to its average volume of 397,131. The stock’s fifty day moving average is $14.88 and its 200-day moving average is $11.42. Centessa Pharmaceuticals plc has a 12 month low of $5.58 and a 12 month high of $17.59. The stock has a market cap of $1.52 billion, a P/E ratio of -10.67 and a beta of 1.46. The company has a quick ratio of 13.29, a current ratio of 13.29 and a debt-to-equity ratio of 0.27.

Centessa Pharmaceuticals (NASDAQ:CNTA) last announced its quarterly earnings results on Tuesday, August 13th. The company reported ($0.40) EPS for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.02). As a group, equities research analysts anticipate that Centessa Pharmaceuticals plc will post -1.68 EPS for the current year.

Hedge Funds Weigh In On Centessa Pharmaceuticals

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Harbour Capital Advisors LLC bought a new stake in shares of Centessa Pharmaceuticals in the 3rd quarter valued at approximately $259,000. GAMMA Investing LLC lifted its stake in shares of Centessa Pharmaceuticals by 103.1% in the 3rd quarter. GAMMA Investing LLC now owns 2,972 shares of the company’s stock valued at $48,000 after purchasing an additional 1,509 shares during the last quarter. Nantahala Capital Management LLC bought a new stake in shares of Centessa Pharmaceuticals during the 2nd quarter worth approximately $4,064,000. Perceptive Advisors LLC lifted its stake in shares of Centessa Pharmaceuticals by 27.6% during the 2nd quarter. Perceptive Advisors LLC now owns 3,933,307 shares of the company’s stock worth $35,518,000 after acquiring an additional 850,000 shares during the last quarter. Finally, Quarry LP lifted its stake in shares of Centessa Pharmaceuticals by 47.8% during the 2nd quarter. Quarry LP now owns 9,608 shares of the company’s stock worth $87,000 after acquiring an additional 3,108 shares during the last quarter. 82.01% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several analysts have issued reports on the company. Jefferies Financial Group boosted their price target on Centessa Pharmaceuticals from $13.00 to $19.00 and gave the company a “buy” rating in a report on Wednesday, September 11th. Guggenheim upped their price objective on Centessa Pharmaceuticals from $20.00 to $24.00 and gave the stock a “buy” rating in a research note on Wednesday, September 11th. BMO Capital Markets upped their price objective on Centessa Pharmaceuticals from $20.00 to $35.00 and gave the stock an “outperform” rating in a research note on Monday, September 16th. Oppenheimer reaffirmed an “outperform” rating and issued a $14.00 price objective on shares of Centessa Pharmaceuticals in a research note on Wednesday, August 14th. Finally, B. Riley initiated coverage on Centessa Pharmaceuticals in a research note on Thursday, September 19th. They issued a “buy” rating and a $33.00 price objective for the company. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $25.17.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.